found that intramyocardial delivery of recombinant SFRP4 protein conferred dose‐dependent cardioprotection, enhancing postinjury cardiac function and suggesting an antifibrotic potential in cardiac ischemia [261]. Here, SFRP4 is linked to myocardial ischemia.